Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Media type: E-Article
Title: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults
Contributor: Sanchez-Sanchez, Juan Luis; Giudici, Kelly V.; Guyonnet, Sophie; Delrieu, Julien; Li, Yan; Bateman, Randall J.; Parini, Angelo; Vellas, Bruno; de Souto Barreto, Philipe; Vellas, Bruno; Guyonnet, Sophie; Carrié, Isabelle; Brigitte, Lauréane; Faisant, Catherine; Lala, Françoise; Delrieu, Julien; Villars, Hélène; Combrouze, Emeline; Badufle, Carole; Zueras, Audrey; Andrieu, Sandrine; Cantet, Christelle; Morin, Christophe; Van Kan, Gabor Abellan; [...]
imprint: Springer Science and Business Media LLC, 2022
Published in: Alzheimer's Research & Therapy
Language: English
DOI: 10.1186/s13195-021-00940-2
ISSN: 1758-9193
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Monocyte Chemoattractant Protein-1 (MCP-1), a glial-derived chemokine, mediates neuroinflammation and may regulate memory outcomes among older adults. We aimed to explore the associations of plasma MCP-1 levels (alone and in combination with β-amyloid deposition—Aβ<jats:sub>42/40</jats:sub>) with overall and domain-specific cognitive evolution among older adults.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Secondary analyses including 1097 subjects (mean age = 75.3 years ± 4.4; 63.8% women) from the Multidomain Alzheimer Preventive Trial (MAPT). MCP-1 (higher is worse) and Aβ<jats:sub>42/40</jats:sub>(lower is worse) were measured in plasma collected at year 1. MCP-1 in continuous and as a dichotomy (values in the highest quartile (MCP-1<jats:sup>+</jats:sup>)) were used, as well as a dichotomy of Aβ<jats:sub>42/40</jats:sub>. Outcomes were measured annually over 4 years and included the following: cognitive composite<jats:italic>z</jats:italic>-score (CCS), the Mini-Mental State Examination (MMSE), and Clinical Dementia Rating (CDR) sum of boxes (overall cognitive function); composite executive function<jats:italic>z</jats:italic>-score, composite attention<jats:italic>z</jats:italic>-score, Free and Cued Selective Reminding Test (FCSRT - memory).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Plasma MCP-1 as a continuous variable was associated with the worsening of episodic memory over 4 years of follow-up, specifically in measures of free and cued delayed recall. MCP-1<jats:sup>+</jats:sup>was associated with worse evolution in the CCS (4-year between-group difference:<jats:italic>β</jats:italic>= −0.14, 95%CI = −0.26, −0.02) and the CDR sum of boxes (2-year:<jats:italic>β</jats:italic>= 0.19, 95%CI = 0.06, 0.32). In domain-specific analyses, MCP-1<jats:sup>+</jats:sup>was associated with declines in the FCSRT delayed recall sub-domains. In the presence of low Aβ<jats:sub>42/40</jats:sub>, MCP-1<jats:sup>+</jats:sup>was not associated with greater declines in cognitive functions. The interaction with continuous biomarker values<jats:italic>Aβ</jats:italic><jats:sub><jats:italic>42/40</jats:italic></jats:sub><jats:italic>× MCP-1 × time</jats:italic>was significant in models with CDR sum of boxes and FCSRT DTR as dependent variables.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Baseline plasma MCP-1 levels were associated with longitudinal declines in overall cognitive and episodic memory performance in older adults over a 4-year follow-up. How plasma MCP-1 interacts with Aβ<jats:sub>42/40</jats:sub>to determine cognitive decline at different stages of cognitive decline/dementia should be clarified by further research. The MCP-1 association on cognitive decline was strongest in those with amyloid plaques, as measured by blood plasma<jats:italic>Aβ</jats:italic><jats:sub><jats:italic>42/40.</jats:italic></jats:sub></jats:p></jats:sec>
Access State: Open Access

Search in field:

Recently searched for: